Company Overview

GRI Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing natural killer T (NKT) cell–targeted therapies to treat inflammatory, autoimmune, and fibrotic diseases. The company operates within the biopharmaceutical and immunology sectors, with a primary emphasis on modulating immune responses through lipid antigen biology. Its business model centers on advancing proprietary small‑molecule and synthetic lipid agonists into clinical development for diseases with high unmet medical need.

The company’s lead programs are designed to selectively activate or regulate NKT cells to restore immune balance without broadly suppressing immune function. GRI Bio’s strategy positions it uniquely within immunology by targeting a specialized immune cell population rather than conventional cytokine or receptor pathways. The company traces its origins to earlier academic and translational research in lipid immunology and has evolved into a publicly traded clinical-stage company focused on pulmonary and systemic inflammatory conditions. Data inconclusive based on available public sources regarding the precise founding year and early corporate lineage.

Business Operations

GRI Bio’s operations are organized around research and development activities, with no commercialized products as of the most recent publicly available filings. The company’s pipeline is led by GRI‑0621, an orally administered small‑molecule NKT cell agonist being evaluated for idiopathic pulmonary fibrosis (IPF) and other fibrotic or inflammatory lung diseases. Revenue generation is currently limited to collaboration income or financing activities, as the company remains pre‑revenue from product sales.

Operational activities are primarily based in the United States, with research conducted through a combination of internal capabilities and outsourced contract research organizations. The company controls proprietary intellectual property related to NKT cell lipid agonists and their therapeutic applications. Data inconclusive based on available public sources regarding any active joint ventures or revenue‑generating partnerships.

Strategic Position & Investments

GRI Bio’s strategic direction is centered on advancing its lead clinical asset through mid‑stage clinical trials while expanding its pipeline of NKT‑focused immunotherapies. Growth initiatives include clinical validation of GRI‑0621 in fibrotic lung diseases and the exploration of additional indications where NKT cell modulation may provide therapeutic benefit. The company has indicated interest in leveraging its platform to develop follow‑on compounds, though specific timelines remain limited in public disclosures.

The company has historically relied on public equity offerings and private placements to fund operations, as reflected in its SEC filings. Data inconclusive based on available public sources regarding significant acquisitions, minority investments, or ownership of notable subsidiaries beyond the core operating entity.

Geographic Footprint

GRI Bio’s primary operational presence is in North America, with corporate headquarters and executive management based in the United States. Clinical development activities may involve trial sites across multiple regions, including potential international locations, depending on study design and regulatory requirements.

While the company does not maintain large-scale international operations, its clinical and regulatory strategy reflects an intent to address global markets, particularly in regions with significant prevalence of fibrotic lung disease. Data inconclusive based on available public sources regarding permanent offices or subsidiaries outside the United States.

Leadership & Governance

GRI Bio is led by an executive team with experience in biotechnology, clinical development, and capital markets. Leadership emphasizes disciplined clinical execution, capital efficiency, and scientific differentiation through targeted immunology.

Key executives include:

• Marc Hertz – President and Chief Executive Officer
• Peter K. Tellone – Chief Financial Officer
• Garett G. Hampton – Chief Scientific Officer
• David J. Johnson – Chief Medical Officer

The board and management team collectively guide corporate governance, strategic planning, and compliance with public company requirements, with oversight aligned to advancing the company’s clinical-stage portfolio.